

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 7, 2009

NEOSTEM, INC.
(Exact name of registrant as specified in its charter)

| | | |
|---|---|---|
| <u>Delaware</u> (State or Other Jurisdiction of Incorporation) | <u>0-10909</u> (Commission File Number) | <u>22-2343568</u> (IRS Employer Identification No.) |
| <u>420 Lexington Avenue, Suite 450 New York, New York</u> (Address of principal executive offices) | | <u>10170</u> (Zip Code) |

Registrant's telephone number, including area code: (212) 584-4180

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

The Company is furnishing herewith the powerpoint presentation included as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 Powerpoint Presentation dated May 7, 2009

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOSTEM, INC.

By: /s/ Catherine M. Vaczy
Catherine M. Vaczy
Vice President and General Counsel

Dated: May 7, 2009

NeoStem[®]

Overview



Robin Smith, MD, MBA
CEO and Chairman of the Board

(NYSE AMEX: NBS)
May 7, 2009

Forward Looking Statements

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements relating to NeoStem, Inc. (the "Company") in general as well as with respect to the Company's proposed merger (the "Merger") with China Biopharmaceuticals Holdings, Inc. ("CBH") and proposed share exchange (the "Share Exchange") whereby the Company would acquire a Hong Kong corporation whose wholly owned subsidiary is entitled to certain benefits from the business, personnel and finance of Shandong New Medicine Research Institute of Integrated and Traditional Western Medicine LLC ("Shandong"), and commencement of independent initiatives in China which may be in lieu of closing on the Share Exchange Agreement with Shandong.

General

Forward looking statements in this presentation include statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELS in that future, the future use of adult stem cells and VSELS as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to manage the business despite continuing operating losses and cash outflows; (ii) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its operations and expansion plans, including meeting its obligations under various licensing arrangements and the successful commercialization of its technology; (iii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of the business; (iv) competitive factors and developments beyond the Company's control; (v) scientific and medical developments beyond the Company's control; (vi) the Company's inability to obtain appropriate governmental licenses or any other adverse effect or limitations caused by government regulation of the business; (vii) whether any of the Company's current or future patent applications result in issued patents; (viii) whether any potential strategic benefits of various licensing transactions will be realized (ix) the Company's ability to maintain its NYSE AMEX listing; and (x) the other factors listed under "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission ("SEC"); and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings".

Proposed Merger; Share Exchange Agreement; Independent China Initiatives

Additional risks and uncertainties relate to the proposed Merger, proposed Share Exchange and the Company's other initiatives in China that may cause actual future experience and results to differ materially from those discussed in these forward-looking statements. Important factors (i) related to the proposed Merger that might cause such a difference include, but are not limited to, costs related to the Merger; failure of the Company's or CBH's stockholders to approve the Merger; the Company's or CBH's inability to satisfy the conditions of the Merger; the Company's inability to maintain its NYSE AMEX listing; the inability to integrate the Company's and CBH's businesses successfully and grow such merged businesses as anticipated and described in this presentation; the need for outside financing to meet capital requirements; failure to have an effective Joint Venture Agreement satisfactory to the parties and regulatory authorities; (ii) related to the Share Exchange that might cause such a difference include, but are not limited to, costs related to the Share Exchange; failure of the Company's stockholders to approve the Share Exchange; an inability to satisfy the conditions of the Share Exchange; the Company's inability to maintain its NYSE AMEX listing; the successful application of the variable interest entity to a prohibited business in China; the inability to integrate the Company's and Shandong's businesses successfully and grow such merged businesses as anticipated and described in this presentation; and the need for outside financing to meet capital requirements; (iii) related to the Company's independent initiatives in China that might cause such a difference include, but are not limited to, costs related to funding these initiatives; the successful application of the variable interest entity to a prohibited business in China; the inability to integrate the Company and the business operations in China successfully and grow such merged businesses as anticipated and described in this presentation; and the need for outside financing to meet capital requirements; and (iv) related to each of the Merger, the Share Exchange and the Company's other initiatives in China, respectively, the other events and factors disclosed in the Company's Form 10-K for the year ended December 31, 2006 and other reports as filed with the SEC.

NeoStem

- **Listed on the NYSE AMEX (ticker: NBS)**
 - **Have completed approximately \$27 Million in financing through April 2009**
 - **Leading operator of commercial autologous adult stem cell bank**
 - Pioneering pre-disease collection, processing and long-term storage of stem cells from adult donors for their own future medical treatment
 - Growing Network in major metropolitan areas in the US
 - Expand Stem Cell Collection Center Network into Montclair, New Jersey and Malibu, California
 - Safe and convenient storage locations
 - Proprietary processes, infrastructure, methods and systems
 - Minimally invasive extraction procedure ("apheresis")
 - Collaborate with Progenitor Cell Therapy to ensure cell processing is at the highest standard of cGMP
 - **Shift toward development therapeutics**
 - Worldwide exclusive license from and continuing collaboration with University of Louisville on VSEL Technology (VSEL very small embryonic like stem cells, found in individuals, may contain many physical characteristics typically found in embryonic stem cells)
 - Worldwide Licenses for Innovative Stem Cell Technology and Applications to Heal Chronic wounds
 - Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
 - Exclusive license to develop orthopedic based therapies in Asia
 - **Expansion into China**
 - Medical tourism due to advanced stem cell therapies developing at a faster pace outside the US
 - Accelerate Stem Cell Therapy
 - Collaborate with PRC experts to accelerate research development activity with licensed technology
-

Adult Stem Cell Collection

- NeoStem has created a safe and minimally invasive way for adults to have their stem cells collected today and stored for future use – “Bio – Insurance”
- NeoStem’s platform enables doctors and patients ready access to their cells as the therapies become available

Collecting Your Stem Cells is To Your Advantage

- Finding a “matching” donor is very difficult
- People are dying while on the wait-list
- High rejection rate due to “graft vs. host” disease (40% even if “perfect match”)
- Risk of transmission of communicable disease
- Possible reluctance to collect and use autologous (self) stem cells once patient is sick because they may have become compromised
- Effects of Age on quantity and quality of stem cells
- Financing available from GE contributing to affordability

70+ Diseases Treated w/Stem Cells

Results for many have been quite encouraging



Heart Disease

"It saved my life... my own stem cells."

BERNIE
Adult Stem Cell Heart Recipient



Lupus

"My Lupus has been in remission for more than 5 years.."

KATHY
Adult Stem Cell Recipient



Multiple Sclerosis

"Stem Cells helped me walk again.."

JANICE
Adult Stem Cell Recipient



Diabetes

"13 out of 14 kids are now off insulin.."

DR. RICHARD BURT
Adult Stem Cell Transplanter, Northwestern Hospital



Scleroderma

"I regained my life again... no more pain"

BRAD
Adult Stem Cell Recipient



Virtually All Therapeutic Areas

Over 2,300 Adult Stem Cell Clinical Trials

- It is forecasted by the end of 2009, the first autologous products will be on the market in both orthopaedic and cardiovascular markets.*
- By 2017, it is forecasted that a minimum of 16 stem cells products will be approved through the FDA and used in 1.9 million annual procedures.*
 - Autoimmune
 - Diabetes/Metabolic
 - Cardiovascular
 - Orthopedic



↑
Non- Closing Fracture

↑
2 Months Post
BMSC
Fully Healed



*Source: Robert Young, RRY Publications, February 2008

Revenue Model

- **Current:**
 - Collection center fees
 - Collection fees from patients
 - Processing and Storage fees (recurring revenue)
 - Usage Fees
 - Federal Funding (awarded)
 - **Potential:**
 - Increase revenue from international collection, processing & storage and usage fees
 - Supplier of stem cells for research
 - Collection fees for trials
 - Government/military contracts
 - SBIR grants
 - Service Agreements
 - Medical Tourism
 - License of Technology
 - Proprietary Advanced Therapies
 - Nutritional Supplement Sales
-


— NeoStem's Future Plan —

- Established and profitable traditional pharma business in China underpins stem cell platform rollout
- Innovative and vertically-integrated regenerative medicine product offering and delivery platform provides high growth opportunity
- Technological, R&D and management resources will help create effective implementation of strategy
- Positions in two of the world's leading healthcare markets by size and potential – US and China
- Wide product offering anticipated, including storage, cosmetics & anti-aging treatment and R&D
- China market presents opportunity with latent domestic demand complemented by medical tourism flows
- NYSE AMEX listed public vehicle

Proposed Combined Company

CBH's pharma revenues and earnings provide certain stability that should be able to underpin the stem cell rollout

NBS brings innovative stem cell technology as well as credibility and domain knowledge which will be a platform for expansion into China



R&D, production and sales of pharmaceutical products as well as chemicals used in pharmaceutical products.

Collection, processing and cryogenic preservation and storage of adult stem cells for potential future regenerative medical treatment.

Provision of stem cell based treatments for cosmetic and anti-aging applications, distribution of related health supplements.

Research and commercial development on VSEL wound healing and orthopedic technology in conjunction with several major PRC medical and US academic medical centers.

Suzhou Erye Pharmaceutical

NBS signed agreement to acquire 51% ownership in Suzhou Erye Pharmaceutical Company in November 2008**

Pharma revenues and earnings provide certain stability that should be able to underpin the stem cell division roll out

- o Provides a stronger balance sheet and P+L
- o Established and profitable traditional pharma business located in Suzhou, Jiangsu Province
- o R&D, production and sales of pharmaceutical products as well as intermediate products
- o 108 products generating US\$49.8 million* in revenues and net profit of US\$8.0 million* in 2008, which will initially be used for plant relocation and capacity expansion
- o Relocation plan for existing plant will offer opportunity to improve manufacturing standards to WHO levels from cGMP, as well as increase capacity
- o Retention of cGMP and adoption of WHO standards will allow future potential in-licensing revenues and export of existing product line
- o US will assist in enhancing pipeline of major products, including new drugs ready for commercialization in China

Comps Analysis – CBH

Pharmaceuticals

| Name | Exchange | Country | Share Price | Mkt Cap (in millions) | EPS 2008 | P/E | |
|--------------------------------|-----------|-----------|-------------|--------------------------|-------------|---------|---------|
| | | | | | | Current | 2008 |
| Qingdao Huaxing Industrials | China | China | \$1.04 | \$564.3 | (\$0.03) | 68.80x | NA |
| S&P Pharmaceutical Industry | China | China | \$2.33 | \$279.7 | (\$0.07) | 22.24x | NA |
| Pharmesis International | Singapore | Singapore | \$0.04 | \$7.5 | \$0.02 | 15.52x | 2.00x |
| North China Pharmaceutical | China | China | \$1.30 | \$1,337.4 | \$0.06 | 32.65x | 21.67x |
| Zhejiang Zhenyuan | China | China | \$1.13 | \$142.0 | \$0.01 | 72.79x | 113.00x |
| Northeast Pharmaceutical Group | China | China | \$3.16 | \$1,054.5 | \$0.17 | 13.89x | 18.59x |
| Jilin Pharmaceutical | China | China | \$1.23 | \$194.6 | \$0.03 | 322.50x | 41.00x |
| Shanghai Pharmaceutical | China | China | \$1.87 | \$1,066.3 | \$0.02 | 73.35x | 93.50x |

| | | |
|---------|---------|--------|
| Max | 322.50x | 88.75x |
| Min | 13.89x | 2.20x |
| Average | 77.72x | 42.09x |
| Median | 50.73x | 32.06x |

*Note: all numbers are in subject to final due diligence; US\$000s; Consolidated numbers reflect 100% revenue recognition, 51% NPAT recognition for Erye.

**Closing is subject to shareholder approval of the Company and China Biopharmaceuticals Holdings

- **Storage**
 - Collection, processing and cryogenic preservation and storage of adult stem cells from peripheral blood for potential future regenerative medical treatment
 - There are no commercial scale providers that offer this service in China
 - Storage is one of the core businesses of NeoStem in the US; Combined Company will be able to derive significant operating support and technical knowledge in establishing, on a commercial scale, such an operation with international best practices and standards

- **Cosmetic & Anti-Aging**
 - Provision of stem cell based treatments for cosmetic and anti-aging applications
 - Distribution of related health supplements and nutraceutical products
 - Distributor network spanning multiple provinces

- **Treatment**
 - Provision of regenerative medicine technologies using autologous mesenchymal stem cells extracted from bone marrow for the treatment of various limb ischemia and orthopedic
 - Provision of regenerative medicine technologies using VSELs for various diseases such as Cardiac Disease, Macular Degeneration, Orthopedic, and Autoimmune Disorders, to name a few.

— Nutritional Supplement —

NeoStem signed an agreement with Ceres Living, Inc. a direct marketing company that developed AIO Premium Cellular Health, a liquid nutritional supplement. AIO was developed in conjunction with a leading nutritional laboratory and NeoStem's scientists and Advisory Board members, based on certain Nutraceuticals which have been shown to optimize stem cell functions.

NeoStem and the Stem for Life Foundation will receive revenues from each sale based on NeoStem's provision to Ceres Living, Inc. of certain scientific literature and access to its scientific personnel.



Intellectual Property

- **Patent Applications Pending on Platform Business:**
 - Collection of adult stem cells from peripheral blood of healthy individuals for future use to treat various diseases of the individual*
 - Process by which NeoStem prepares and stores stem cells collected from peripheral blood by apheresis following mobilization of stem cells from bone marrow
 - NeoStem's low-dose, short course, cytokine induction of stem cell mobilization


- **Patent Applications pending on Very Small Embryonic – Like (VSEL) Stem Cell Technology exclusively licensed from the University of Louisville in November 2007:**
 - Identification, isolation, and use of population of stem cells isolated from bone marrow, umbilical cord blood, and/or other sources and that are referred to as Very Small Embryonic-Like (VSEL) stem cells
 - Therapeutic treatment of various diseases with VSELs, including myocardial infarction, ischemic injury and stroke

*Each application above is pending in China except for this application.

Intellectual Property

- **Patent Applications Pending on Therapeutic Uses of Stem Cells:**
 - Vincent Falanga
 - Composition and Methods Using Stem Cells in Cutaneous Wound Healing
 - Vincent Giampapa
 - Method and Composition for Restoration of Age-Related Tissue Loss in the Face or Selected Areas of the Body
 - Regenexx; Christopher Centeno
 - Mesenchymal Stem Cell Isolation and Transplantation Method and System to be Used in a Clinical Setting (Orthopedic Uses)
 - Methods and Compositions for the Optimized Expansion and Implantation of Mesenchymal Stem Cells
 - Compositions and Methods for Cartilage Intervertebral Disc Repair
 - Compositions to Promote Implantation and Engraftment of Stem Cells
-

Very-Small Embryonic-like Stem Cells (VSELs)





Leukemia (2006), 1-7

Morphological and molecular characterization of novel population of CXCR4⁺ SSEA-4⁺ Oct-4⁺ very small embryonic-like cells purified from human cord blood – preliminary report

M Kucia¹, M Halasa², M Wysoczynski¹, M Baskiewicz-Masiuk², S Moldenhauer¹, E Zuba-Surma¹, R Czajka², W Wojakowski¹, B Machalinski² and MZ Ratajczak¹

Each of us has a population of very primitive embryonic like stem cells that have remained in our bodies since birth

- Can be mobilized in the blood using NeoStem Process
- Should be easily recovered
- Cryopreserved
- Used for future therapeutic use



Current Capitalization

| | <u>May 5, 2009</u> | |
|--|------------------------------|------------|
| | # of Shares | |
| Preferred stock; authorized, 5,000,000 shares | | |
| Series B convertible preferred stock, authorized, 825,000 shares | | 10,000 |
| Series D convertible preferred stock, authorized, 880,000 shares* | | 880,000 |
| Common stock, authorized, 500,000,000 shares; | | 7,917,406 |
| | Average Exercise Price | |
| Warrants Outstanding | \$ 3.19 | 14,105,962 |
| Stock Options Outstanding | \$ 3.96 | 1,718,300 |

*Upon shareholder approval the Series D convertible preferred will be converted into 8,800,000 common shares

Comparables

Market Price as of Jan-6-2009
All amounts in USD millions except for per share data (share price denoted in local currency)

| Company | Ticker | Share Price | 52-Week High | % of 52-Wk Hi | Mkt Cap | Ent Value | LTM Revenue | LTM EBITDA | LTM Net Income | MRQ Total Assets | MRQ Book Value | Mkt Cap/Rev | EV/Rev | EV/EBITDA | Mkt Cap/EBITDA | P/E | P/B | Assets/Equity | Mkt Cap/Assets |
|---------------------------------|------------|--------------|--------------|---------------|------------|------------|-------------|--------------|----------------|------------------|----------------|-------------|-------------|-----------|----------------|-----------|------------|---------------|----------------|
| Neostem | NBS | 0.560 | 2.240 | 25.0% | 4.1 | 3.6 | 0.2 | (9.1) | (9.2) | 2.3 | 1.8 | 19.8 | 17.6 | NM | NM | NM | 2.2 | 1.3 | 1.8 |
| LifeStem Int'l (fmr Calbiatech) | LSTM.ob | 0.004 | 2.000 | 0.2% | 0.3 | NA | 1.2 | (1.0) | (1.1) | 0.5 | (4.1) | 0.2 | NA | NA | NM | NM | NM | NM | 0.5 |
| Cord Blood America | CBAI.ob | 0.002 | 0.070 | 2.6% | 0.5 | NA | 3.4 | (3.3) | (7.2) | 5.5 | (7.3) | 0.2 | NA | NA | NM | NM | NM | NM | 0.1 |
| Cryo-Cell Int'l | CCEL.ob | 0.595 | 1.920 | 31.0% | 7.0 | 2.6 | 17.4 | (1.1) | (2.5) | 10.9 | (7.1) | 0.4 | 0.2 | NM | NM | NM | NM | NM | 0.6 |
| ViaCell (purchased by PKI) | VIAC | 7.250 | NA | NA | 300.0 | 260.0 | 67.0 | (19.1) | (18.6) | 76.2 | 26.6 | 4.5 | 3.9 | NM | NM | NM | 11.3 | 2.9 | 3.9 |
| Aastrom Biosciences | ASTM | 0.570 | 0.840 | 67.9% | 76.9 | 60.7 | 0.5 | (19.1) | (19.0) | 22.3 | 19.8 | 166.5 | 131.4 | NM | NM | NM | 3.9 | 1.1 | 3.4 |
| Advanced Cell Technology | ACTC.ob | 0.065 | 0.320 | 20.3% | 6.7 | 14.7 | 0.6 | (19.2) | (0.7) | 7.0 | (28.0) | 10.3 | 22.6 | NM | NM | NM | NM | NM | 1.0 |
| BioLife Solutions | BLFS.ob | 0.040 | 0.120 | 33.3% | 2.8 | 7.2 | 1.2 | (2.4) | (2.7) | 1.3 | (4.4) | 2.3 | 5.9 | NM | NM | NM | NM | NM | 2.1 |
| Bio-Matrix | BMSN.ob | 0.250 | 1.290 | 19.4% | 6.5 | 7.9 | NA | (3.0) | (3.1) | 1.2 | (0.3) | NA | NA | NM | NM | NM | NM | NM | 5.6 |
| Brainstorm Cell Therapeutics | BCLL.ob | 0.080 | 1.130 | 7.1% | 4.4 | 4.9 | NA | (4.0) | (4.8) | 1.1 | (1.8) | NA | NA | NM | NM | NM | NM | NM | 4.2 |
| Curis | CRIS | 0.880 | 1.940 | 45.4% | 55.9 | 20.8 | 16.8 | (6.0) | (5.7) | 41.5 | 38.8 | 3.3 | 1.2 | NM | NM | NM | 1.4 | 1.1 | 1.3 |
| Cytori Therapeutics | CYTX | 3.880 | 8.560 | 45.3% | 113.5 | 94.5 | 4.7 | (30.7) | (34.2) | 26.7 | (2.3) | 24.0 | 20.0 | NM | NM | NM | NM | NM | 4.3 |
| Geron | GERN | 5.140 | 5.610 | 91.6% | 406.9 | 221.5 | 7.0 | (61.5) | (60.9) | 187.9 | 179.3 | 58.5 | 31.9 | NM | NM | NM | 2.3 | 1.0 | 2.2 |
| MediStem | MEDS.ob | 0.150 | 6.500 | 2.3% | 0.7 | 0.0 | 1.6 | (1.1) | (1.5) | 1.1 | 1.1 | 0.5 | 0.0 | NM | NM | NM | 0.7 | 1.0 | 0.6 |
| MultiCell Technologies | MCET.ob | 0.008 | 0.210 | 3.8% | 0.6 | NA | 0.3 | (1.1) | (1.3) | 1.2 | (3.0) | 2.4 | NA | NA | NM | NM | NM | NM | 0.5 |
| Applied Wellness | AWLL.ob | 0.002 | 0.500 | 0.4% | 0.0 | NA | 1.0 | (0.5) | (0.6) | 0.2 | (1.1) | 0.0 | NA | NA | NM | NM | NM | NM | 0.0 |
| Opexa Therapeutics | OPXA | 0.329 | 3.930 | 8.4% | 4.0 | (0.6) | NA | (13.6) | (13.7) | 5.5 | 3.3 | NA | NA | NM | NM | NM | 1.2 | 1.7 | 0.7 |
| Oxiris Therapeutics | OSIR | 20.240 | 21.650 | 93.5% | 643.9 | 641.8 | 18.3 | (68.5) | (77.1) | 28.5 | (8.2) | 35.3 | 35.1 | NM | NM | NM | NM | NM | 22.6 |
| Stem Cell Innovations | SCLL.ob | 0.008 | 0.020 | 37.5% | 0.0 | 9.9 | 0.2 | NA | NA | NA | 0.1 | 66.0 | NA | NA | NA | NA | NA | NA | NA |
| Stem Cell Therapy | SCTL.ob | 0.080 | 0.400 | 20.0% | 3.77 | 3.5 | 0.0 | NA | (1.7) | 0.1 | (1.0) | 125.7 | 118.0 | NA | NA | NM | NM | NM | 31.2 |
| StemCells Inc. | STEM | 1.600 | 2.480 | 64.5% | 129.8 | 101.5 | 89.3 | (26.0) | (26.8) | 28.5 | 17.9 | 1.5 | 1.1 | NM | NM | NM | 7.3 | 1.6 | 4.6 |
| Theragenesis Corp. | KOOL | 0.550 | 2.120 | 25.9% | 30.8 | 5.7 | 22.8 | (9.9) | (9.6) | 34.3 | 28.0 | 1.4 | 0.2 | NM | NM | NM | 1.1 | 1.2 | 0.9 |
| NeuralStem | CUR | 1.570 | 3.450 | 45.5% | 50.5 | 47.5 | NM | (10.5) | (11.3) | 5.9 | 4.6 | NA | NA | NM | NM | NM | 11.0 | 1.3 | 8.6 |
| Pluristem Therapeutics | PSTI | 0.440 | 5.990 | 7.3% | 3.7 | 1.8 | NA | (10.1) | (10.5) | 4.2 | 3.1 | NA | NA | NM | NM | NM | 1.2 | 1.3 | 0.9 |
| StemLife | 0137.KL | 1.080 | 3.940 | 27.4% | 50.8 | 43.3 | 5.8 | 1.7 | 1.6 | 14.2 | 10.8 | 8.7 | 7.4 | 25.3 | 29.6 | 32.3 | 4.7 | 1.3 | 3.6 |
| Athersys | ATHX | 0.600 | 5.000 | 12.0% | 11.4 | (22.1) | 3.6 | (19.3) | (18.0) | 38.7 | 35.7 | 3.1 | NM | NM | NM | NM | 0.3 | 1.1 | 0.3 |
| Stem Cell Sciences | STEM.LN | 0.080 | 0.307 | 26.1% | NA | NA | 1.2 | (6.7) | (7.0) | 9.7 | 7.9 | NA | NA | NA | NA | NA | NA | 1.2 | NA |
| Epistem | BHP.LN | 2.125 | 2.250 | 94.4% | 23.0 | 19.5 | 4.1 | (2.7) | (2.3) | 6.3 | 5.1 | 5.6 | 4.7 | NM | NM | NM | 4.5 | 1.2 | 3.6 |
| ReNeuron | RENE.LN | 0.026 | 0.210 | 12.4% | 6.4 | 0.9 | 0.1 | (13.5) | (13.2) | 15.4 | 13.8 | 127.4 | 18.6 | NM | NM | NM | 0.5 | 1.1 | 0.4 |
| Intercytex | ICX.LN | 0.270 | 0.544 | 49.7% | 34.6 | NA | 0.2 | (23.0) | (21.0) | 30.1 | 25.7 | 157.2 | NA | NA | NA | NM | 1.3 | 1.2 | 1.2 |
| Cryo-Save Group | CRYO.LN | 0.380 | 2.125 | 17.9% | 26.5 | (31.0) | 17.7 | 7.2 | 5.3 | 75.7 | 62.6 | 1.5 | NM | NM | 3.7 | 5.0 | 0.4 | 1.2 | 0.4 |
| Min | | | | 0.2% | 0.0 | (31.0) | 0.0 | (68.5) | (77.1) | 0.1 | (28.0) | 0.0 | 0.0 | 25.3 | 3.7 | 5.0 | 0.3 | 1.0 | 0.0 |
| Mean | | | | 31.5% | 69.0 | 63.2 | 11.4 | (13.1) | (12.7) | 23.5 | 14.3 | 30.9 | 27.6 | 25.3 | 16.6 | 18.7 | 3.3 | 1.3 | 3.9 |
| Median | | | | 25.9% | 7.0 | 8.9 | 3.4 | (8.3) | (7.0) | 9.7 | 3.3 | 3.2 | 7.4 | 25.3 | 16.6 | 18.7 | 1.4 | 1.2 | 1.2 |
| Max | | | | 94.4% | 643.9 | 641.8 | 89.3 | 7.2 | 5.3 | 187.9 | 179.3 | 166.5 | 131.4 | 25.3 | 29.6 | 32.3 | 11.3 | 2.9 | 31.2 |

*ViaCell share price as of Nov 30 2007 (closing date of transaction with PKI) and financial data as of Sep 31 2007 (the company's last SEC filing)

*Stem Cell Innovations financial data as of Jun 30 2007; enterprise value calculated using Jun 30 2007 net debt and Jan 6 2009 market cap

*StemLife financial data is as of Dec 31 2007; enterprise value calculated using Dec 31 2007 net cash and Jan 6 2009 market cap

*Caella Healthcare financial data as of Mar 31 2008

*Financial data for companies listed on the LN exchange are as of the latest reported semi-annual period, either Jun 30 2008 or Dec 31 2007



Current Advisory Board Members

- **Wayne A. Marasco, M.D., Ph.D.** Chairman - Chairman of Scientific Advisory Board. Associate Professor-Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He is taking the lead in expanding the Company's academic relationships and research collaborations.
 - **Douglas W. Losordo, MD** - For many years a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth's Medical Center in Boston, Dr. Losordo was recently appointed Professor of Medicine at Northwestern University and Director of the Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine. A Fellow or Member of many national professional organizations, he currently serves on committees of the American College of Cardiology, the American Diabetes Association and the American Society of Gene Therapy where he chairs the Cardiovascular Gene Therapy Committee. Dr. Losordo serves as Principal Investigator in many grant research projects and has published widely, contributing to more than 300 professional articles, abstracts and book chapters in recent years. He also serves on the Editorial Boards of numerous medical specialty journals including *Stem Cells*, *Vascular Medicine* and *Circulation Research*.
 - **Ron Rothenberg MD, FACEP** - Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certified by the American Board of Anti-Aging Medicine. A graduate of Columbia University, College of Physicians and Surgeons, and a specialist in Emergency Medicine at Los Angeles County-USC Medical Center, he has served as Clinical Professor of Preventive and Family Medicine at the UCSD School of Medicine Clinical Facility. He is currently Attending Physician at Scripps Memorial Hospital in Encinitas.
 - **Richard Gatti, MD** - Dr. Richard Gatti, a professor at the University of California, Los Angeles (UCLA) and renowned Pathologist at the UCLA Medical Center, was one of the early pioneers of bone marrow transplantation, among the earliest known forms of adult stem cell therapeutics, for immunodeficiency in the late sixties. Dr. Gatti is also a leading authority in the field of gene therapeutics and has authored or co-authored hundreds of papers related to the molecular identification and treatment of genetic disorders. He has worked for many years to help find a cure for Ataxia-Telangiectasia, a progressive neurological disorder of childhood, associated with increased cancer risk, immunodeficiency, radiosensitivity, and cell cycle defects.
 - **Neil Livingstone, PhD** - Dr. Livingstone is currently the Chairman and Chief Executive Officer of ExecutiveAction LLC. He was the founder and, until January, 2007, Chief Executive Officer of GlobalOptions Inc., which went public in 2005. He is also Lead Director of Erickson Air-Crane, a \$200 million helicopter company. Dr. Livingstone has noted expertise on national security, and is the author of nine books on terrorism. He has served on advisory panels to The Secretary of State, The Chief of Naval Operations, and The Pentagon. He has testified before Congress and delivered more than 500 major addresses in the U.S. and abroad, including recent speeches at The House of Commons and The United Nations. Dr. Livingstone serves on numerous advisory boards, including Supercom Inc., Digital Ally, the Africa Society, and No Greater Love. He was the Founder and Chairman of the Institute on Terrorism and Sub-national Conflict and served as President of Watergate South for more than seven years.
 - **Bradford Billet, OBE CEM** - Mr. Billet is an executive with the City of New York, where his responsibilities include matters of international affairs, security and emergency management. He is also chairman of the Billet Group, a management consulting company. During the past 20 plus years, Mr. Billet has acquired extensive experience in International Affairs, Emergency Management, Security, Governmental and Business Management, Administration and Operational disciplines. He has held high-ranking positions in both the private and public sectors with budgets in excess of 180 million dollars. Mr. Billet has responded, coordinated and directed multi agency emergency operations, including the September 11th attacks and the 1993 bombing of the World Trade Center, 20 aviation accidents as well as numerous manmade and natural disasters, involving mass casualties and/or fatalities.
 - **Douglas Wynyard** - Mr. Douglas Wynyard is a Senior Vice President for Nordblom Company, a full-service commercial real estate firm headquartered in the Boston area. He is experienced in real estate development, asset management, leasing, investment sales, and marketing. He also represents numerous corporations with the planning, acquisition and disposition of their facilities. Having received a Bachelor's degree in Zoology from Bristol University, Mr. Wynyard is passionate about the biological sciences and is an investor in a number of medtech companies.
-

Contact Information

Robin Smith, MD MBA
Chairman & CEO
Direct: (212) 584-4174
Email: rsmith@neostem.com

NeoStem, Inc.
420 Lexington Avenue
Suite 450
New York, NY 10170
Main: (212) 584-4180
Fax: (646) 514-7787
www.neostem.com
1.888.STEM BANK
